Access the full text.
Sign up today, get DeepDyve free for 14 days.
D de Zeeuw, DA Anzalone, VA Cain, MD Cressman, HJ Heerspink, BA Molitoris, JT Monyak, HH Parving, G Remuzzi, JR Sowers, DG. Vidt (2015)
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trialJ Clin Pathol, 3
AT Clarke, PC Johnson, GC Hall, I Ford, PR. Mills (2016)
High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD CohortAm J Cardiol, 11
J. Tobert, C. Newman (2016)
The nocebo effect in the context of statin intolerance.Journal of clinical lipidology, 10 4
A Verhulst, PC D'Haese, ME. De Broe (2004)
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cellsCardiology, 15
C Wanner, M Tonelli (2014)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patientJ Am Coll Cardiol, 85
R. Giugliano, S. Wiviott, M. Blazing, G. Ferrari, Jeong-Gun Park, S. Murphy, Jennifer White, A. Tershakovec, C. Cannon, E. Braunwald (2017)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT TrialJAMA Cardiology, 2
R. Scott, V. Lagou, R. Welch, E. Wheeler, May Montasser, J. Luan, R. Mägi, R. Strawbridge, E. Rehnberg, S. Gustafsson, S. Kanoni, L. Rasmussen-Torvik, L. Yengo, C. Lecoeur, D. Shungin, S. Sanna, C. Sidore, Paul Johnson, J. Jukema, T. Johnson, A. Mahajan, N. Verweij, G. Thorleifsson, J. Hottenga, Sonia Shah, A. Smith, B. Sennblad, C. Gieger, P. Salo, M. Perola, N. Timpson, David Evans, B. Pourcain, Ying Wu, Jeanette Andrews, J. Hui, L. Bielak, Wei Zhao, M. Horikoshi, P. Navarro, A. Isaacs, J. O’Connell, K. Stirrups, V. Vitart, C. Hayward, T. Esko, E. Mihailov, Ross Fraser, T. Fall, B. Voight, S. Raychaudhuri, Han Chen, C. Lindgren, Andrew Morris, N. Rayner, N. Robertson, D. Rybin, Ching‐Ti Liu, J. Beckmann, Sara Willems, P. Chines, A. Jackson, H. Kang, H. Stringham, Kijoung Song, Toshiko Tanaka, J. Peden, A. Goel, A. Hicks, P. An, M. Müller-Nurasyid, A. Franco-Cereceda, L. Folkersen, L. Marullo, H. Jansen, A. Oldehinkel, M. Bruinenberg, J. Pankow, K. North, N. Forouhi, R. Loos, S. Edkins, T. Varga, G. Hallmans, H. Oksa, Mulas Antonella, R. Nagaraja, S. Trompet, I. Ford, S. Bakker, A. Kong, M. Kumari, B. Gigante, C. Herder, P. Munroe, M. Caulfield, J. Antti, M. Mangino, K. Small, I. Miljkovic, Yongmei Liu, M. Atalay, W. Kiess, A. James, F. Rivadeneira, A. Uitterlinden, C. Palmer, A. Doney, G. Willemsen, J. Smit, Susan Campbell, O. Polašek, L. Bonnycastle, S. Hercberg, M. Dimitriou, J. Bolton, G. Fowkes, P. Kovacs, J. Lindström, T. Zemunik, S. Bandinelli, S. Wild, H. Basart, W. Rathmann, H. Grallert, W. Maerz, W. Maerz, M. Kleber, B. Boehm, A. Peters, P. Pramstaller, M. Province, I. Borecki, N. Hastie, I. Rudan, H. Campbell, H. Watkins, M. Farrall, M. Stumvoll, L. Ferrucci, D. Waterworth, R. Bergman, F. Collins, J. Tuomilehto, R. Watanabe, E. Geus, B. Penninx, A. Hofman, B. Oostra, B. Psaty, P. Vollenweider, James Wilson, A. Wright, G. Hovingh, A. Metspalu, M. Uusitupa, P. Magnusson, K. Kyvik, J. Kaprio, J. Price, G. Dedoussis, P. Deloukas, P. Meneton, L. Lind, M. Boehnke, A. Shuldiner, C. Duijn, A. Morris, A. Toenjes, P. Peyser, J. Beilby, J. Beilby, A. Körner, J. Kuusisto, M. Laakso, S. Bornstein, P. Schwarz, T. Lakka, R. Rauramaa, L. Adair, G. Smith, T. Spector, T. Illig, U. Faire, A. Hamsten, V. Gudnason, M. Kivimäki, A. Hingorani, S. Keinänen-Kiukaanniemi, T. Saaristo, D. Boomsma, K. Stefánsson, P. Harst, J. Dupuis, N. Pedersen, N. Sattar, T. Harris, F. Cucca, S. Ripatti, V. Salomaa, K. Mohlke, B. Balkau, P. Froguel, P. Froguel, P. Froguel, A. Pouta, M. Järvelin, N. Wareham, N. Bouatia-Naji, M. McCarthy, P. Franks, J. Meigs, Tanya Teslovich, J. Florez, C. Langenberg, E. Ingelsson, I. Prokopenko, I. Barroso (2012)
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathwaysNature Genetics, 44
M Benn, R Frikke-Schmidt, BG Nordestgaard, A. Tybjærg-Hansen (2017)
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer?s disease and Parkinson?s disease: mendelian randomisation studyLancet, 357
H Bays, DE Cohen, N Chalasani, SA. Harrison (2014)
The National Lipid Association's Statin Safety Task Force. An assessment by the statin liver safety task force: 2014 updatePharmacogenomics, 8
V. Athyros, D. Mikhailidis, A. Papageorgiou, A. Symeonidis, A. Pehlivanidis, V. Bouloukos, M. Elisaf (2004)
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) studyJournal of Clinical Pathology, 57
Kowa Pharmaceutical Europe Co . Ltd . Livazo Consolidated SmPC . Summary of Product Characteristics Pravastatin Sodium 40 mg Tablets . Summary of Product Characteristics
V. Athyros, K. Tziomalos, T. Gossios, T. Griva, P. Anagnostis, Konstantinos Kargiotis, E. Pagourelias, E. Theocharidou, A. Karagiannis, D. Mikhailidis (2010)
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisThe Lancet, 376
J Leuschen, EM Mortensen, CR Frei, EA Mansi, V Panday, I. Mansi (2013)
Association of statin use with cataracts: a propensity score-matched analysisBMJ, 131
E. Brunner, C. Welch, M. Shipley, S. Ahmadi-Abhari, A. Singh‐Manoux, M. Kivimäki (2016)
Midlife Risk Factors for Impaired Physical and Cognitive Functioning at Older Ages: A Cohort StudyThe Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 72
J Hippisley-Cox, C. Coupland (2010)
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseJ Am Soc Nephrol, 340
G. Boysen (2009)
European Guidelines on Cardiovascular Disease PreventionInternational Journal of Stroke, 4
NL Saunders, MJ. Summers (2011)
Longitudinal deficits to attention, executive, and working memory in subtypes of mild cognitive impairmentJAMA Cardiol, 25
J. Perk, G. Backer, H. Gohlke, I. Graham, eljko Reiner, Monique Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cífková, C. Deaton, S. Ebrahim, Miles Fisher, G. Germano, R. Hobbs, A. Hoes, Ş. Karadeniz, A. Mezzani, E. Prescott, L. Rydén, M. Scherer, M. Syvänne, W. Reimer, C. Vrints, D. Wood, J. Zamorano, F. Zannad (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)European Journal of Preventive Cardiology, 19
EV Perdices, I Medina-Cáliz, S Hernando, A Ortega, F Martín-Ocaña, JM Navarro, G Peláez, A Castiella, H Hallal, M Romero-Gómez, A González-Jiménez, M Robles-Díaz, MI Lucena, RJ. Andrade (2014)
Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity RegistryJ Clin Lipidol, 106
S Lim, P. Barter (2014)
Antioxidant effects of statins in the management of cardiometabolic disordersJ Am Heart Assoc, 21
D. Swerdlow, D. Preiss, K. Kuchenbaecker, M. Holmes, J. Engmann, T. Shah, R. Sofat, S. Stender, Paul Johnson, R. Scott, M. Leusink, N. Verweij, S. Sharp, Yiran Guo, C. Giambartolomei, C. Chung, A. Peasey, A. Amuzu, Kawah Li, J. Palmen, Philip Howard, J. Cooper, F. Drenos, Yun Li, G. Lowe, J. Gallacher, Marlene Stewart, I. Tzoulaki, S. Buxbaum, D. A, N. Forouhi, N. Onland-Moret, Y. Schouw, R. Schnabel, J. Hubacek, R. Kubínová, M. Baceviciene, A. Tamošiūnas, A. Pająk, R. Topor-Madry, U. Stepaniak, S. Malyutina, D. Baldassarre, B. Sennblad, E. Tremoli, U. Faire, F. Veglia, I. Ford, J. Jukema, R. Westendorp, G. Borst, P. Jong, A. Algra, W. Spiering, Anke Zee, O. Klungel, A. Boer, P. Doevendans, C. Eaton, Jennifer Robinson, D. Duggan, J. Kjekshus, J. Downs, A. Gotto, A. Keech, R. Marchioli, G. Tognoni, P. Sever, N. Poulter, D. Waters, T. Pedersen, P. Amarenco, H. Nakamura, J. McMurray, J. Lewsey, D. Chasman, P. Ridker, A. Maggioni, L. Tavazzi, K. Ray, S. Seshasai, J. Manson, J. Price, P. Whincup, R. Morris, D. Lawlor, G. Smith, Y. Ben-Shlomo, P. Schreiner, M. Fornage, D. Siscovick, M. Cushman, M. Kumari, N. Wareham, W. Verschuren, S. Redline, S. Patel, J. Whittaker, A. Hamsten, J. Delaney, C. Dale, Tom Gaunt, A. Wong, D. Kuh, R. Hardy, S. Kathiresan, B. Castillo, P. Harst, E. Brunner, A. Tybjaerg-hansen, M. Marmot, R. Krauss, M. Tsai, J. Coresh, R. Hoogeveen, B. Psaty, L. Lange, H. Hakonarson, F. Dudbridge, S. Humphries, P. Talmud, M. Kivimäki, N. Timpson, C. Langenberg, F. Asselbergs, M. Voevoda, M. Bobák, H. Pikhart, James Wilson, A. Reiner, B. Keating, A. Hingorani, N. Sattar (2015)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsLancet, 385
A. Laties, C. Shear, E. Lippa, A. Gould, H. Taylor, D. Hurley, W. Stephenson, E. Keates, M. Tupy-Visich, A. Chremos (1991)
Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.The American journal of cardiology, 67 6
B. Ference, H. Ginsberg, I. Graham, K. Ray, J. Chris, Packard, E. Bruckert, R. Hegele, R. Krauss, F. Raal, H. Schunkert, G. Watts, J. Borén, S. Fazio, J. Horton, L. Masana, S. Nicholls, B. Nordestgaard, B. Sluis, M. Taskinen, U. Landmesser, U. Laufs, O. Wiklund, Jane Stock, M. Chapman, A. Catapano (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease
Chintan Desai, S. Martin, R. Blumenthal (2014)
Non-cardiovascular effects associated with statinsThe BMJ, 349
N Chalasani, RJ Fontana, HL Bonkovsky, PB Watkins, T Davern, J Serrano, H Yang, J Rochon (2008)
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United StatesBest Pract Res Clin Endocrinol Metab, 135
J. Fulcher, R. O'Connell, M. Voysey, J. Emberson, L. Blackwell, B. Mihaylova, J. Simes, R. Collins, A. Kirby, H. Colhoun, E. Braunwald, J. Rosa, T. Pedersen, A. Tonkin, Barry Davis, P. Sleight, M. Franzosi, C. Baigent, A. Keech (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsThe Lancet, 385
Ajay Gupta, D. Thompson, A. Whitehouse, T. Collier, B. Dahlöf, N. Poulter, R. Collins, P. Sever, Ascot Investigators (2018)
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseYearbook of Paediatric Endocrinology
E. Stroes, P. Thompson, A. Corsini, G. Vladutiu, F. Raal, K. Ray, M. Roden, Evan Stein, L. Tokgözoğlu, B. Nordestgaard, E. Bruckert, G. Backer, R. Krauss, U. Laufs, R. Santos, R. Hegele, G. Hovingh, Lawrence Leiter, F. Mach, Winfried März, C. Newman, O. Wiklund, T. Jacobson, A. Catapano, M. Chapman, H. Ginsberg, E. Stroes, P. Thompson, A. Corsini, G. Vladutiu, F. Raal, K. Ray, M. Roden, Evan Stein, L. Tokgözoğlu, B. Nordestgaard, Éric Bruckert, Ronald Krauss, U. Laufs, R. Santos, Winfried März, C. Newman, M. Chapman, H. Ginsberg, G. Backer, A. Catapano, R. Hegele, G. Hovingh, T. Jacobson, L. Leiter, F. Mach, O. Wiklund (2015)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementEuropean Heart Journal, 36
A. Clarke, Paul Johnson, G. Hall, I. Ford, P. Mills (2016)
High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD CohortPLoS ONE, 11
Catapano (2016)
2016 ESC/EAS Guidelines for the management of dyslipidaemiasEur Heart J, 37
D. Harnois (2009)
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesYearbook of Medicine, 2009
D. Nikolić, M. Banach, S. Nikfar, P. Salari, D. Mikhailidis, P. Toth, M. Abdollahi, K. Ray, M. Pencina, J. Małyszko, J. Rysz, M. Rizzo (2013)
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?International journal of cardiology, 168 6
HPS3/TIMI55–REVEAL Collaborative Group (2017)
Effects of anacetrapib in patients with atherosclerotic vascular diseaseN Engl J Med, 377
C. Bang, A. Greve, M. Cour, K. Boman, C. Gohlke-Bärwolf, S. Ray, T. Pedersen, A. Rossebø, P. Okin, R. Devereux, K. Wachtell (2015)
Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).The American journal of cardiology, 116 12
C Baigent, L Blackwell, J Emberson, LE Holland, C Reith, N Bhala, R Peto, EH Barnes, A Keech, J Simes, R. Collins (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trialsRev Esp Enferm Dig, 376
M. Benn, B. Nordestgaard, R. Frikke-Schmidt, A. Tybjærg‐Hansen (2017)
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation studyThe BMJ, 357
C. Sirtori (2014)
The pharmacology of statins.Pharmacological research, 88
(2015)
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy182/4987130 by guest on
X Su, L Zhang, J Lv, J Wang, W Hou, X Xie, H. Zhang (2016)
Effect of statins on kidney disease outcomes: a systematic review and meta-analysisInt J Cardiol, 67
MW Russo, JH Hoofnagle, J Gu, RJ Fontana, H Barnhart, DE Kleiner, N Chalasani, HL. Bonkovsky (2014)
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury networkGastroenterology, 60
R. Giugliano, T. Pedersen, Jeong-Gun Park, G. Ferrari, Z. Gaciong, R. Češka, K. Tóth, I. Gouni-Berthold, J. López-Miranda, F. Schiele, F. Mach, B. Ott, Estella Kanevsky, Armando Pineda, R. Somaratne, S. Wasserman, A. Keech, P. Sever, M. Sabatine (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialThe Lancet, 390
(2015)
Cholesterol Treatment Trialists
D. Vidt, M. Cressman, S. Harris, J. Pears, H. Hutchinson (2004)
Rosuvastatin-Induced Arrest in Progression of Renal DiseaseCardiology, 102
RW. Mahley (2016)
Central nervous system lipoproteins: apoE and regulation of cholesterol metabolismExpert Rev Cardiovasc Ther, 36
S. Trompet, Peter Van, Vliet Ae, A. Craen, Ae Jelle, Jolles Ae, B. Buckley, M. Murphy, I. Ford, Ae Peter, W. Macfarlane, Ae Naveed, Sattar Ae, C. Packard, Ae David, J. Stott, Ae Jim, Shepherd Ae, E. Bollen, Ae Gerard, J. Blauw, Ae Wouter, Jukema Ae, R. Westendorp, S. Trompet, Á. Vliet, A. Craen, G. Blauw, Á. Westendorp, J. Jukema, J. Jolles, B. Buckley, Á. Murphy, I. Ford, P. Macfarlane, N. Sattar, C. Packard, Á. Shepherd, D. Stott, E. Bollen, R. Westendorp (2009)
Pravastatin and cognitive function in the elderly. Results of the PROSPER studyJournal of Neurology, 257
W Hou, J Lv, V Perkovic, L Yang, N Zhao, MJ Jardine, A Cass, H Zhang, H. Wang (2013)
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysisLancet Diabetes Endocrinol, 34
D. Salat, R. Ribosa, L. Garcia-Bonilla, J. Montaner (2009)
Statin use before and after acute ischemic stroke onset improves neurological outcomeExpert Review of Cardiovascular Therapy, 7
M. Simons, P. Keller, J. Dichgans, J. Schulz (2001)
Cholesterol and Alzheimer’s diseaseNeurology, 57
R. Giugliano, M. Sabatine, B. Ott (2017)
Cognitive Function in a Randomized Trial of Evolocumab.The New England journal of medicine, 377 20
DG Vidt, MD Cressman, S Harris, JS Pears, HG. Hutchinson (2004)
Rosuvastatin-induced arrest in progression of renal diseaseLancet, 102
(2017)
Important safety label changes to cholesterol-lowering statin drugs
S. Yusuf, J. Bosch, G. Dagenais, Jun Zhu, D. Xavier, Li-sheng Liu, P. Pais, P. López-Jaramillo, Lawrence Leiter, A. Dans, Á. Avezum, L. Piegas, A. Parkhomenko, K. Keltai, M. Keltai, K. Sliwa, R. Peters, C. Held, Irina Chazova, K. Yusoff, B. Lewis, P. Janský, K. Khunti, W. Toff, C. Reid, J. Varigos, G. Sánchez-Vallejo, R. McKelvie, J. Pogue, Hyejung Jung, P. Gao, R. Diaz, E. Lonn (2016)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.The New England journal of medicine, 374 21
M Tonelli, L Moyé, FM Sacks, T Cole, GC Curhan (2003)
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular diseasePharmacol Res, 14
Yu Song, H. Nie, Yong Xu, Ling Zhang, Yan Wu (2013)
Association of statin use with risk of dementia: A meta‐analysis of prospective cohort studiesGeriatrics & Gerontology International, 13
K Richardson, M Schoen, B French, CA Umscheid, MD Mitchell, SE Arnold, PA Heidenreich, DJ Rader, EM. deGoma (2013)
Statins and cognitive function: a systematic reviewGer Gerontol Int, 159
J. Szendroedi, C. Anderwald, M. Krššák, M. Bayerle‐Eder, H. Esterbauer, G. Pfeiler, A. Brehm, P. Nowotny, A. Hofer, W. Waldhäusl, M. Roden (2009)
Effects of High-Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Nonobese Type 2 Diabetic PatientsDiabetes Care, 32
RG Kim, R Loomba, LJ Prokop, S. Singh (2017)
Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysisAtherosclerosis, 15
S. Boekholdt, G. Hovingh, S. Mora, B. Arsenault, P. Amarenco, T. Pedersen, J. Larosa, D. Waters, D. Demicco, R. Simes, A. Keech, D. Colquhoun, G. Hitman, D. Betteridge, M. Clearfield, J. Downs, H. Colhoun, A. Gotto, P. Ridker, S. Grundy, J. Kastelein (2014)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.Journal of the American College of Cardiology, 64 5
Jared Sturgeon, A. Folsom, W. Longstreth, E. Shahar, W. Rosamond, M. Cushman (2007)
Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective StudyStroke, 38
C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, C Wanner, V Krane, A Cass, J Craig, B Neal, L Jiang, LS Hooi, A Levin, L Agodoa, M Gaziano, B Kasiske, R Walker, ZA Massy, B Feldt-Rasmussen, U Krairittichai, V Ophascharoensuk, B Fellström, H Holdaas, V Tesar, A Wiecek, D Grobbee, D de Zeeuw, C Grönhagen-Riska, T Dasgupta, D Lewis, W Herrington, M Mafham, W Majoni, K Wallendszus, R Grimm, T Pedersen, J Tobert, J Armitage, A Baxter, C Bray, Y Chen, Z Chen, M Hill, C Knott, S Parish, D Simpson, P Sleight, A Young, R Collins (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialCochrane Database Syst. Rev, 377
RP Giugliano, F Mach, K Zavitz, C Kurtz, K Im, E Kanevsky, J Schneider, H Wang, A Keech, TR Pedersen, MS Sabatine, PS Sever, JG Robinson, N Honarpour, SM Wasserman, BR Ott (2017)
Cognitive function in a randomized trial of evolocumabJ Gen Intern Med, 377
H. Naci, J. Brugts, T. Ades (2013)
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled TrialsCirculation: Cardiovascular Quality and Outcomes, 6
Gupta (2017)
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseLancet, 389
MD Vergouwen, RJ de Haan, M Vermeulen, YB. Roos (2008)
Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular diseaseLancet, 39
D. Waters, J. Ho, S. Boekholdt, D. Demicco, J. Kastelein, Michael Messig, A. Breazna, T. Pedersen (2012)
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.Journal of the American College of Cardiology, 61 2
B. Ference, Jennifer Robinson, Robert Brook, A. Catapano, M. Chapman, David Neff, S. Voros, Robert Giugliano, George Smith, S. Fazio, M. Sabatine, H. M.P. (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.The New England journal of medicine, 375 22
SM Boekholdt, GK Hovingh, S Mora, BJ Arsenault, P Amarenco, TR Pedersen, JC LaRosa, DD Waters, DA DeMicco, RJ Simes, AC Keech, D Colquhoun, GA Hitman, DJ Betteridge, MB Clearfield, JR Downs, HM Colhoun, AM Gotto, PM Ridker, SM Grundy, JJ. Kastelein (2014)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trialsN Engl J Med, 64
A. Corsini, M. Bortolini (2013)
Drug‐Induced Liver Injury: The Role of Drug Metabolism and TransportThe Journal of Clinical Pharmacology, 53
(2016)
Authors/Task Force Members
曲东锋 (2004)
Stroke Prevention by Aggressive Reduction in Cholesterol Levels, 12
(2010)
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary
PK Elias, MF Elias, RB D'Agostino, LM Sullivan, PA. Wolf (2005)
Serum cholesterol and cognitive performance in the Framingham Heart StudyJAMA, 67
A. Sorokin, Jennifer Brown, P. Thompson (2007)
Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.Atherosclerosis, 194 2
M. DeGorter, R. Tirona, U. Schwarz, Yun-Hee Choi, G. Dresser, N. Suskin, K. Myers, Guangyong Zou, O. Iwuchukwu, Wei Wei, R. Wilke, R. Hegele, R. Kim (2013)
Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical CareCirculation: Cardiovascular Genetics, 6
E. Björnsson, Elin Jacobsen, E. Kalaitzakis (2012)
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.Journal of hepatology, 56 2
O. Hockwin, M. Evans, S. Roberts, R. Stoll (1990)
Post-mortem biochemistry of beagle dog lenses after treatment with Fluvastatin (Sandoz) for 2 years at different dose levels.Lens and eye toxicity research, 7 3-4
J. Betteridge, R. Carmena (2016)
The diabetogenic action of statins — mechanisms and clinical implicationsNature Reviews Endocrinology, 12
E. Kesse‐Guyot, V. Andreeva, M. Touvier, C. Jeandel, M. Ferry, S. Hercberg, P. Galan, T. Group (2015)
Overall and abdominal adiposity in midlife and subsequent cognitive functionThe journal of nutrition, health & aging, 19
H. Cederberg, A. Stančáková, Nagendra Yaluri, S. Modi, J. Kuusisto, M. Laakso (2015)
Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohortDiabetologia, 58
D. Zeeuw, D. Anzalone, V. Cain, M. Cressman, H. Heerspink, B. Molitoris, J. Monyak, H. Parving, G. Remuzzi, J. Sowers, D. Vidt (2015)
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.The lancet. Diabetes & endocrinology, 3 3
N. Sattar, D. Preiss, H. Murray (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 375
Marisa Schoen, K. Richardson, B. French, Matthew Mitchell, S. Arnold, P. Heidenreich, D. Rader, C. Umscheid, Emil Degoma (2014)
Statins and Cognitive Function: A Systematic Review†∗Journal of Clinical Lipidology, 8
Nichole Saunders, M. Summers (2011)
Longitudinal deficits to attention, executive, and working memory in subtypes of mild cognitive impairment.Neuropsychology, 25 2
Huichun Xu, K. Ryan, T. Jaworek, L. Southam, J. Reid, J. Overton, A. Baras, M. Puurunen, E. Zeggini, Simeon Taylor, A. Shuldiner, B. Mitchell (2017)
Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish, 66
G Zhong, Y Wang, Y Zhang, JJ Guo, Y. Zhao (2015)
Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiersJ Gerontol A Biol Sci Med Sci, 10
D Nikolic, M Banach, S Nikfar, P Salari, DP Mikhailidis, PP Toth, M Abdollahi, KK Ray, MJ Pencina, J Malyszko, J Rysz, M Rizzo (2013)
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?J Am Soc Nephrol, 168
G. Ducrocq, P. Steg (2015)
Treating coronary artery disease in patients with a history of cerebrovascular disease.Archives of cardiovascular diseases, 108 11
L. Bowman, J. Hopewell, F. Chen, K. Wallendszus, W. Stevens (2018)
Effects of Anacetrapib in Patients With Atherosclerotic Vascular DiseaseJournal of Vascular Surgery, 67
BR Ott, LA Daiello, IJ Dahabreh, BA Springate, K Bixby, M Murali, TA. Trikalinos (2015)
Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trialsAnn Intern Med, 30
W. Herrington, J. Emberson, B. Mihaylova, L. Blackwell, C. Reith, M. Solbu, P. Mark, B. Fellström, A. Jardine, C. Wanner, H. Holdaas, J. Fulcher, R. Haynes, M. Landray, A. Keech, J. Simes, R. Collins, C. Baigent (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.The lancet. Diabetes & endocrinology, 4 10
MJ Koren, MS Sabatine, RP Giugliano, G Langslet, SD Wiviott, H Kassahun, A Ruzza, Y Ma, R Somaratne, FJ. Raal (2017)
Long-term low-density lipoprotein cholesterol?lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia. Results up to 4 years from the open-label OSLER-1 Extension StudyJ Neurol, 2
K. Ray, S. Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, S. Nethercott, D. Preiss, S. Erqou, N. Sattar (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsThe Lancet, 373
A Sanguankeo, S Upala, W Cheungpasitporn, P Ungprasert, EL. Knight (2015)
Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysisAm J Cardiol, 10
B. Fellström, A. Jardine, R. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D. Chae, A. Chevaile, S. Cobbe, C. Grönhagen‐Riska, J. Lima, R. Lins, G. Mayer, Alan McMahon, H. Parving, G. Remuzzi, O. Samuelsson, S. Sonkodi, D. Sci, G. Süleymanlar, D. Tsakiris, V. Tesar, V. Todorov, A. Więcek, R. Wüthrich, Mattis Gottlow, E. Johnsson, F. Zannad (2009)
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.The New England journal of medicine, 360 14
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
CS Desai, SS Martin, RS. Blumenthal (2014)
Non-cardiovascular effects associated with statinsStroke, 349
D. Healy, R. Morgan, S. Chinnaswamy (2009)
Transient global amnesia associated with statin intakeBMJ Case Reports, 2009
A. Vallejo-Vaz, S. Seshasai, K. Kurogi, I. Michishita, T. Nozue, S. Sugiyama, S. Tsimikas, H. Yoshida, K. Ray (2015)
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.Atherosclerosis, 241 2
AM Laties, CL Shear, EA Lippa, AL Gould, HR Taylor, DP Hurley, WP Stephenson, EU Keates, MA Tupy-Visich, AN. Chremos (1991)
Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatinN Engl J Med, 67
D. Preiss, S. Seshasai, P. Welsh, S. Murphy, J. Ho, D. Waters, D. Demicco, P. Barter, C. Cannon, M. Sabatine, E. Braunwald, J. Kastelein, J. Lemos, M. Blazing, T. Pedersen, M. Tikkanen, N. Sattar, K. Ray (2011)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.JAMA, 305 24
Z Zhang, P Wu, J Zhang, S Wang, G. Zhang (2016)
The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: a meta-analysisAm J Cardiol, 105
S Yu, Y Chu, G Li, L Ren, Q Zhang, L. Wu (2017)
Statin use and the risk of cataracts: a systematic review and meta?AnalysisBr J Ophthalmol, 6
Shan-dong Yu, Yanpeng Chu, Gang Li, L. Ren, Qing Zhang, Lin Wu (2017)
Statin Use and the Risk of Cataracts: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
T. Yamazaki, J. Kishimoto, C. Ito, M. Noda, M. Odawara, Y. Terauchi, T. Shiba, H. Kitazato, Y. Iwamoto, Y. Akanuma, T. Kadowaki, F. Investigators (2011)
Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patientsDiabetology International, 2
C. Baigent, M. Landray, C. Reith, J. Emberson, D. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, Lixin Jiang, L. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellström, H. Holdaas, V. Tesar, A. Więcek, D. Grobbee, D. Zeeuw, C. Grönhagen‐Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Yiping Chen, Zhengming Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young, R. Collins (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet, 377
R. Kim, R. Loomba, L. Prokop, Siddharth Singh (2017)
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysisClinical Gastroenterology & Hepatology, 15
C. Wanner, V. Krane, W. März, M. Olschewski, J. Mann, G. Ruf, E. Ritz (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.The New England journal of medicine, 353 3
M. Vergouwen, M. Vermeulen, Y. Roos (2009)
HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDYNeurology, 72
P. Amarenco, J. Bogousslavsky, Callahan rd, L. Goldstein, M. Hennerici, A. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K. Welch, J. Zivin, Stroke Investigators (2006)
High-dose atorvastatin after stroke or transient ischemic attack.The New England Journal of Medicine, 355
Xiaole Su, Luxia Zhang, J. Lv, Jinwei Wang, W. Hou, Xinfang Xie, Hong Zhang (2016)
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation, 67 6
M Casula, D Soranna, G Corrao, L Merlino, AL Catapano, E. Tragni (2016)
Statin use and risk of cataract: a nested case-control study within a healthcare databaseCirculation, 251
(2018)
Adverse effects of statin therapy 2539 Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/27/2526/4987130 by UNIVERSITA' DEGLI STUDI DI MILANO user on
Zhenhong Zhang, Pingsheng Wu, Jiping Zhang, Shunyin Wang, Gengxin Zhang (2016)
The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.Pharmacological research, 105
J. Hippisley-Cox, C. Coupland (2010)
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseThe BMJ, 340
M. Koren, M. Sabatine, R. Giugliano, G. Langslet, S. Wiviott, H. Kassahun, A. Ruzza, Yuhui Ma, R. Somaratne, F. Raal (2017)
Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension StudyJAMA Cardiology, 2
E. Org, Y. Blum, S. Kasela, M. Mehrabian, J. Kuusisto, A. Kangas, P. Soininen, Zeneng Wang, M. Ala-Korpela, S. Hazen, M. Laakso, A. Lusis (2017)
Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohortGenome Biology, 18
C. Dormuth, B. Hemmelgarn, J. Paterson, M. James, G. Teare, C. Raymond, J. Lafrance, A. Levy, A. Garg, P. Ernst (2013)
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databasesBMJ : British Medical Journal, 346
C. Wanner, M. Tonelli (2014)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.Kidney international, 85 6
P. Ridker, A. Pradhan, J. Macfadyen, P. Libby, R. Glynn (2012)
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialThe Lancet, 380
Stephanie Wise, N. Nathoo, M. Etminan, F. Mikelberg, G. Mancini (2014)
Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States.The Canadian journal of cardiology, 30 12
E Kesse-Guyot, VA Andreeva, M Touvier, C Jeandel, M Ferry, S Hercberg, P Galan (2015)
Overall and abdominal adiposity in midlife and subsequent cognitive functionArterioscler Thromb Vasc Biol, 19
L. Lotta, S. Sharp, S. Burgess, J. Perry, I. Stewart, Sara Willems, J. Luan, E. Ardanaz, L. Arrióla, B. Balkau, H. Boeing, P. Deloukas, N. Forouhi, P. Franks, S. Grioni, R. Kaaks, T. Key, C. Navarro, P. Nilsson, K. Overvad, D. Palli, S. Panico, J. Quirós, E. Riboli, O. Rolandsson, C. Sacerdote, Elena Salamanca, N. Slimani, A. Spijkerman, A. Tjønneland, R. Tumino, D. A, Y. Schouw, M. McCarthy, I. Barroso, S. O’Rahilly, D. Savage, N. Sattar, C. Langenberg, R. Scott, N. Wareham (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.JAMA, 316 13
J. McKinney, W. Kostis (2012)
Statin Therapy and the Risk of Intracerebral Hemorrhage: A Meta-Analysis of 31 Randomized Controlled TrialsStroke, 43
J. Besseling, J. Kastelein, J. Defesche, B. Hutten, G. Hovingh (2015)
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.JAMA, 313 10
M. Goodarzi, Xiaohui Li, R. Krauss, J. Rotter, Y. Chen (2013)
Relationship of Sex to Diabetes Risk in Statin TrialsDiabetes Care, 36
E. Speliotes, C. Willer, S. Berndt, K. Monda, G. Thorleifsson, A. Jackson, H. Allen, C. Lindgren, J. Luan, R. Maegi, J. Randall, S. Vedantam, T. Winkler, L. Qi, T. Workalemahu, I. Heid, V. Steinthorsdottir, H. Stringham, M. Weedon, E. Wheeler, A. Wood, T. Ferreira, R. Weyant, A. Segrè, K. Estrada, L. Liang, J. Nemesh, Ju-Hyun Park, S. Gustafsson, Tuomas Kilpelaenen, Jian Yang, N. Bouatia-Naji, T. Esko, M. Feitosa, Z. Kutalik, M. Mangino, S. Raychaudhuri, A. Scherag, A. Smith, Ryan Welch, J. Zhao, K. Aben, D. Absher, N. Amin, A. Dixon, E. Fisher, N. Glazer, M. Goddard, N. Heard-Costa, Volker Hoesel, J. Hottenga, Å. Johansson, T. Johnson, Shamika Ketkar, C. Lamina, Shengxu Li, M. Moffatt, R. Myers, Narisu Narisu, J. Perry, M. Peters, Michael Preuss, S. Ripatti, F. Rivadeneira, C. Sandholt, L. Scott, N. Timpson, J. Tyrer, S. Wingerden, R. Watanabe, Charles White, F. Wiklund, C. Barlassina, D. Chasman, M. Cooper, J. Jansson, R. Lawrence, Niina Pellikka, I. Prokopenko, Jianxin Shi, E. Thiering, Helene Alavere, M. Alibrandi, P. Almgren, A. Arnold, T. Aspelund, L. Atwood, B. Balkau, A. Balmforth, A. Bennett, Y. Ben-Shlomo, R. Bergman, S. Bergmann, H. Biebermann, A. Blakemore, T. Boes, L. Bonnycastle, S. Bornstein, Morris Brown, T. Buchanan, F. Busonero, H. Campbell, F. Cappuccio, Christine Cavalcanti-Proença, Y. Chen, Chih-Mei Chen, P. Chines, R. Clarke, L. Coin, J. Connell, I. Day, M. Heijer, J. Duan, S. Ebrahim, P. Elliott, R. Elosúa, G. Eiriksdottir, M. Erdos, J. Eriksson, M. Facheris, S. Felix, P. Fischer-Posovszky, A. Folsom, N. Friedrich, N. Freimer, Mao Fu, Stefan Gaget, P. Gejman, E. Geus, C. Gieger, A. Gjesing, A. Goel, P. Goyette, H. Grallert, J. Graessler, D. Greenawalt, C. Groves, V. Gudnason, C. Guiducci, A. Hartikainen, N. Hassanali, A. Hall, A. Havulinna, C. Hayward, A. Heath, C. Hengstenberg, A. Hicks, A. Hinney, A. Hofman, G. Homuth, J. Hui, W. Igl, C. Iribarren, B. Isomaa, K. Jacobs, I. Jarick, E. Jewell, U. John, T. Jørgensen, P. Jousilahti, A. Jula, M. Kaakinen, E. Kajantie, L. Kaplan, S. Kathiresan, J. Kettunen, L. Kinnunen, J. Knowles, I. Kolčić, I. Koenig, S. Koskinen, P. Kovacs, J. Kuusisto, P. Kraft, K. Kvaløy, J. Laitinen, O. Lantieri, C. Lanzani, L. Launer, C. Lecoeur, Terho Lehtimaeki, G. Lettre, Jianjun Liu, M. Lokki, M. Lorentzon, R. Luben, B. Ludwig, P. Manunta, Diana Marek, M. Marre, N. Martin, W. McArdle, A. McCarthy, B. McKnight, T. Meitinger, O. Melander, D. Meyre, K. Midthjell, G. Montgomery, M. Morken, A. Morris, R. Mulić, J. Ngwa, M. Nelis, M. Neville, D. Nyholt, C. O’Donnell, S. O’Rahilly, K. Ong, B. Oostra, G. Paré, A. Parker, M. Perola, I. Pichler, Kirsi Pietilaeinen, Carl Platou, O. Polašek, A. Pouta, S. Rafelt, O. Raitakari, N. Rayner, M. Ridderstråle, W. Rief, A. Ruokonen, N. Robertson, P. Rzehak, V. Salomaa, A. Sanders, M. Sandhu, S. Sanna, J. Saramies, M. Savolainen, S. Scherag, S. Schipf, S. Schreiber, H. Schunkert, K. Silander, J. Sinisalo, D. Siscovick, J. Smit, N. Soranzo, U. Sovio, J. Stephens, I. Surakka, A. Swift, Mari-Liis Tammesoo, J. Tardif, M. Teder-Laving, Tanya Teslovich, J. Thompson, Brian Thomson, A. Toenjes, T. Tuomi, J. Meurs, G. Ommen, V. Vatin, J. Viikari, S. Visvikis-Siest, V. Vitart, C. Vogel, B. Voight, L. Waite, H. Wallaschofski, G. Walters, E. Widén, S. Wiegand, S. Wild, G. Willemsen, D. Witte, J. Witteman, Jianfeng Xu, Qunyuan Zhang, L. Zgaga, A. Ziegler, P. Zitting, J. Beilby, I. Farooqi, J. Hebebrand, H. Huikuri, A. James, M. Kaehoenen, D. Levinson, F. Macciardi, M. Nieminen, C. Ohlsson, L. Palmer, P. Ridker, M. Stumvoll, J. Beckmann, H. Boeing, E. Boerwinkle, D. Boomsma, M. Caulfield, S. Chanock, F. Collins, L. Cupples, G. Smith, J. Erdmann, P. Froguel, Henrik Greonberg, U. Gyllensten, P. Hall, T. Hansen, T. Harris, A. Hattersley, R. Hayes, J. Heinrich, F. Hu, K. Hveem, T. Illig, M. Järvelin, J. Kaprio, F. Karpe, K. Khaw, L. Kiemeney, H. Krude, M. Laakso, D. Lawlor, A. Metspalu, P. Munroe, W. Ouwehand, O. Pedersen, B. Penninx, A. Peters, P. Pramstaller, T. Quertermous, T. Reinehr, A. Rissanen, I. Rudan, N. Samani, P. Schwarz, A. Shuldiner, T. Spector, J. Tuomilehto, M. Uda, A. Uitterlinden, T. Valle, M. Wabitsch, G. Waeber, N. Wareham, H. Watkins, James Wilson, A. Wright, M. Zillikens, N. Chatterjee, S. Mccarroll, S. Purcell, E. Schadt, P. Visscher, T. Assimes, I. Borecki, P. Deloukas, C. Fox, L. Groop, T. Haritunians, D. Hunter, R. Kaplan, K. Mohlke, J. O’Connell, L. Peltonen, D. Schlessinger, D. Strachan, C. Duijn, H. Wichmann, T. Frayling, U. Thorsteinsdóttir, G. Abecasis, I. Barroso, M. Boehnke, K. Stefánsson, K. North, M. McCarthy, J. Hirschhorn, E. Ingelsson, R. Loos (2012)
Association analyses of 249 , 796 individuals reveal 18 new loci associated with body mass index
H Naci, J Brugts, T. Ades (2013)
Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trialsHepatology, 6
A. Koudinov, T. Berezov, N. Koudinova (2002)
Cholesterol and Alzheimer's disease: is there a link?Neurology, 58 7
DG Hackam, M Woodward, LK Newby, DL Bhatt, M Shao, EE Smith, A Donner, M Mamdani, JD Douketis, H Arima, J Chalmers, S MacMahon, DL Tirschwell, BM Psaty, CD Bushnell, MI Aguilar, DJ Capampangan, DJ Werring, P De Rango, A Viswanathan, N Danchin, CL Cheng, YH Yang, BM Verdel, MS Lai, J Kennedy, S Uchiyama, T Yamaguchi, Y Ikeda, M. Mrkobrada (2011)
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysisNeurology, 124
H. Bays, D. Cohen, N. Chalasani, S. Harrison, The Tas (2014)
An assessment by the Statin Liver Safety Task Force: 2014 update.Journal of clinical lipidology, 8 3 Suppl
N. Chalasani, R. Fontana, H. Bonkovsky, P. Watkins, T. Davern, J. Serrano, Hongqiu Yang, J. Rochon (2008)
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.Gastroenterology, 135 6
M. Black (1983)
Drug induced liver disease.Postgraduate medical journal, 59 Suppl 4
P. Toth (2012)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialYearbook of Endocrinology, 2012
B. McGuinness, John O'Hare, R. Bullock, R. Malouf, D. Craig, P. Passmore (2010)
Statins for the treatment of dementiaAlzheimer's & Dementia, 6
S. Feasson (2008)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial
JE Sidaway, RG Davidson, F McTaggart, TC Orton, RC Scott, GJ Smith, NJ. Brunskill (2004)
Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cellsExpert Opin Drug Safety, 15
S. Nielsen, B. Nordestgaard (2016)
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study.European heart journal, 37 11
PM Ridker, J MacFadyen, M Cressman, RJ. Glynn (2010)
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trialKidney Int, 55
RJ Andrade, M Robles, E Ulzurrun, MI. Lucena (2009)
Drug?induced liver injury: insights from genetic studiesClin Gastroenterol Hepatol, 10
Soo Lim, P. Barter (2014)
Antioxidant effects of statins in the management of cardiometabolic disorders.Journal of atherosclerosis and thrombosis, 21 10
M. Davidson (2004)
Rosuvastatin safety: lessons from the FDA review and post-approval surveillanceExpert Opinion on Drug Safety, 3
A. Corsini, P. Ganey, C. Ju, N. Kaplowitz, D. Pessayre, R. Roth, P. Watkins, M. Albassam, Baolian Liu, Saray Stancic, L. Suter, M. Bortolini (2012)
Current challenges and controversies in drug-induced liver injury.Drug safety, 35 12
K. Tolman (2002)
The liver and lovastatin.The American journal of cardiology, 89 12
S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, P López-Jaramillo, LA Leiter, A Dans, A Avezum, LS Piegas, A Parkhomenko, K Keltai, M Keltai, K Sliwa, RJ Peters, C Held, I Chazova, K Yusoff, BS Lewis, P Jansky, K Khunti, WD Toff, CM Reid, J Varigos, G Sanchez-Vallejo, R McKelvie, J Pogue, H Jung, P Gao, R Diaz, E Lonn (2016)
Cholesterol lowering in intermediate-risk persons without cardiovascular diseaseLens Eye Toxic Res, 374
C Herrick, M Litvin, AC. Goldberg (2014)
Lipid lowering in liver and chronic kidney diseaseLancet, 28
S Trompet, P van Vliet, AJ de Craen, J Jolles, BM Buckley, MB Murphy, I Ford, PW Macfarlane, N Sattar, CJ Packard, DJ Stott, J Shepherd, EL Bollen, GJ Blauw, JW Jukema, RG. Westendorp (2010)
Pravastatin and cognitive function in the elderly. Results of the PROSPER studyPLoS One, 257
BC Fellström, AG Jardine, RE Schmieder, H Holdaas, K Bannister, J Beutler, DW Chae, A Chevaile, SM Cobbe, C Grönhagen-Riska, JJ De Lima, R Lins, G Mayer, AW McMahon, HH Parving, G Remuzzi, O Samuelsson, S Sonkodi, D Sci, G Süleymanlar, D Tsakiris, V Tesar, V Todorov, A Wiecek, RP Wüthrich, M Gottlow, E Johnsson, F Zannad (2009)
Rosuvastatin and cardiovascular events in patients undergoing hemodialysisEur Heart J, 360
CR Dormuth, BR Hemmelgarn, JM Paterson, MT James, GF Teare, CB Raymond, JP Lafrance, A Levy, AX Garg, P Ernst (2013)
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databasesJ Amn Soc Nephrol, 346
L. Farrer, L. Cupples, J. Haines, B. Hyman, W. Kukull, R. Mayeux, R. Myers, M. Pericak-Vance, N. Risch, C. Duijn (1997)
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysisJAMA, 278
W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, Elizabeth Walker, David Nathan (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.The New England journal of medicine, 346 6
P. Würtz, Qin Wang, P. Soininen, A. Kangas, G. Fatemifar, Tuulia Tynkkynen, M. Tiainen, M. Perola, T. Tillin, A. Hughes, P. Mäntyselkä, M. Kähönen, T. Lehtimäki, N. Sattar, A. Hingorani, J. Casas, V. Salomaa, M. Kivimäki, M. Järvelin, G. Smith, M. Vanhala, D. Lawlor, O. Raitakari, N. Chaturvedi, J. Kettunen, M. Ala-Korpela (2016)
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA ReductaseJournal of the American College of Cardiology, 67
Jessica Leuschen, E. Mortensen, C. Frei, Eva Mansi, V. Panday, I. Mansi (2013)
Association of statin use with cataracts: a propensity score-matched analysis.JAMA ophthalmology, 131 11
S. Bangalore, R. Fayyad, G. Hovingh, R. Laskey, L. Vogt, D. Demicco, D. Waters (2014)
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.The American journal of cardiology, 113 12
M. Sabatine, Lawrence Leiter, S. Wiviott, R. Giugliano, P. Deedwania, G. Ferrari, S. Murphy, J. Kuder, I. Gouni-Berthold, B. Lewis, Y. Handelsman, A. Pineda, N. Honarpour, A. Keech, P. Sever, T. Pedersen (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.The lancet. Diabetes & endocrinology, 5 12
S. Melmed (2016)
New therapeutic agents for acromegalyNature Reviews Endocrinology, 12
O Hockwin, M Evans, SA Roberts, RE. Stoll (1990)
Post-mortem biochemistry of beagle dog lenses after treatment with Fluvastatin (Sandoz) for 2 years at different dose levelsAtherosclerosis, 7
A Singh-Manoux, D Gimeno, M Kivimaki, E Brunner, MG. Marmot (2008)
Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II studyN Engl J Med, 28
Massimo Piepoli, Arno Hoes, Stefan Agewall, Christian Albus, C. Brotons, A. Catapano, M. Cooney, U. Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Hall, F. Hobbs, M. Løchen, Herbert Löllgen, Pedro Marques-Vidal, J. Perk, E. Prescott, Josep Redon, Dimitrios Richter, Naveed Sattar, Yvo Smulders, M. Tiberi, H. Worp, I. Dis, W. Verschuren, Guy Backer, M. Roffi, Victor Aboyans, Norbert Bachl, Héctor Bueno, S. Carerj, Leslie Cho, John Cox, J. Sutter, Günther Egidi, Miles Fisher, Donna Fitzsimons, Oscar Franco, Maxime Guenoun, C. Jennings, Borut Jug, Paulus Kirchhof, K. Kotseva, G. Lip, François Mach, G. Mancia, Franz Bermudo, A. Mezzani, A. Niessner, Piotr Ponikowski, Bernhard Rauch, Lars Rydén, Adrienne Stauder, Guillaume Turc, Olov Wiklund, Stephan Windecker, J. Zamorano (2012)
2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Journal of Preventive Cardiology, 23
P. Ridker, J. Macfadyen, M. Cressman, R. Glynn (2010)
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.Journal of the American College of Cardiology, 55 12
C. Baigent, L. Blackwell, J. Emberson, L. Holland, C. Reith, N. Bhala, R. Peto, E. Barnes, A. Keech, J. Simes, R. Collins (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsLancet, 376
SC Palmer, SD Navaneethan, JC Craig, DW Johnson, V Perkovic, J Hegbrant, GF. Strippoli (2014)
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisJ Am Coll Cardiol
S Bangalore, R Fayyad, GK Hovingh, R Laskey, L Vogt, DA DeMicco, DD Waters (2014)
Statin and the risk of renal-related serious adverse events: analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trialsBMJ, 113
P. Kohli, D. Waters, R. Nemr, B. Arsenault, Michael Messig, D. Demicco, R. Laskey, J. Kastelein (2015)
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.Journal of the American College of Cardiology, 65 4
SJ Wise, NA Nathoo, M Etminan, FS Mikelberg, GB. Mancini (2014)
Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United StatesJAMA Ophthalmol, 30
R. Collins, C. Reith, J. Emberson, J. Armitage, C. Baigent, L. Blackwell, R. Blumenthal, J. Danesh, G. Smith, D. DeMets, Stephen Evans, M. Law, S. MacMahon, S. Martin, B. Neal, N. Poulter, D. Preiss, P. Ridker, Ian Roberts, A. Rodgers, P. Sandercock, K. Schulz, P. Sever, J. Simes, L. Smeeth, N. Wald, S. Yusuf, R. Peto (2016)
Interpretation of the evidence for the efficacy and safety of statin therapyThe Lancet, 388
G. Zhong, Yi Wang, Yong Zhang, J. Guo, Yong Zhao (2015)
Smoking Is Associated with an Increased Risk of Dementia: A Meta-Analysis of Prospective Cohort Studies with Investigation of Potential Effect ModifiersPLoS ONE, 10
C. Newman, J. Tsai, M. Szarek, Don Luo, E. Gibson (2006)
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.The American journal of cardiology, 97 1
H. Zimmerman (1978)
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
H. Colhoun, D. Betteridge, P. Durrington, G. Hitman, H. Neil, S. Livingstone, M. Thomason, M. Mackness, V. Charlton-menys, J. Fuller (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 364
D. Freeman, J. Norrie, N. Sattar, R. Neely, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard, J. Shepherd, A. Gaw (2001)
Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention StudyCirculation: Journal of the American Heart Association, 103
S. Navaneethan, V. Perkovic, David Johnson, S. Nigwekar, J. Craig, G. Strippoli (2009)
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.The Cochrane database of systematic reviews, 2
D Healy, R Morgan, S. Chinnaswamy (2009)
Transient global amnesia associated with statin intakeLancet
ML Harris, AJ Bron, NA Brown, AC Keech, KR Wallendszus, JM Armitage, S MacMahon, G Snibson, R. Collins (1995)
Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study GroupCan J Cardiol, 79
RP Giugliano, TR Pedersen, JG Park, GM De Ferrari, ZA Gaciong, R Ceska, K Toth, I Gouni-Berthold, J Lopez-Miranda, F Schiele, F Mach, BR Ott, E Kanevsky, AL Pineda, R Somaratne, SM Wasserman, AC Keech, PS Sever, MS Sabatine (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialCochrane Database Syst Rev, 390
B. Ott, L. Daiello, I. Dahabreh, B. Springate, Kimberly Bixby, Manjari Murali, T. Trikalinos (2015)
Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled TrialsJournal of General Internal Medicine, 30
MH. Davidson (2004)
Rosuvastatin safety: lessons from the FDA review and post-approval surveillanceN Engl J Med, 3
D Salat, R Ribosa, L Garcia-Bonilla, J. Montaner (2009)
Statin use before and after acute ischemic stroke onset improves neurological outcomeNeurology, 7
VG Athyros, K Tziomalos, TD Gossios, T Griva, P Anagnostis, K Kargiotis, ED Pagourelias, E Theocharidou, A Karagiannis, DP Mikhailidis (2010)
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisDig Liver Dis, 376
VG Athyros, DP Mikhailidis, AA Papageorgiou, AN Symeonidis, AN Pehlivanidis, VI Bouloukos, M. Elisaf (2004)
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) studyLancet, 57
G. Mancini, S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, J. Genest, M. Gupta, R. Hegele, D. Ng, G. Pearson, J. Pope, A. Tashakkor (2016)
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).The Canadian journal of cardiology, 32 7 Suppl
KG. Tolman (2002)
The liver and lovastatinJ Clin Pharmacol, 89
A. Schmidt, D. Swerdlow, D. Swerdlow, M. Holmes, M. Holmes, R. Patel, R. Patel, Z. Fairhurst-Hunter, D. Lyall, F. Hartwig, B. Horta, E. Hyppönen, C. Power, M. Moldovan, Max Moldovan, E. Iperen, G. Hovingh, I. Demuth, K. Norman, E. Steinhagen-Thiessen, Juri Demuth, L. Bertram, L. Bertram, Tian Liu, S. Coassin, J. Willeit, S. Kiechl, K. Willeit, D. Mason, John Wright, R. Morris, Goya Wanamethee, P. Whincup, Y. Ben-Shlomo, S. McLachlan, J. Price, M. Kivimäki, C. Welch, A. Sánchez-Gálvez, P. Marques-Vidal, A. Nicolaides, A. Nicolaides, A. Panayiotou, N. Onland-Moret, Y. Schouw, G. Matullo, G. Fiorito, S. Guarrera, C. Sacerdote, N. Wareham, C. Langenberg, R. Scott, J. Luan, M. Bobák, S. Malyutina, A. Pająk, R. Kubínová, A. Tamošiūnas, H. Pikhart, L. Husemoen, N. Grarup, O. Pedersen, T. Hansen, A. Linneberg, K. Simonsen, J. Cooper, S. Humphries, M. Brilliant, Terrie Kitchner, H. Hakonarson, D. Carrell, C. McCarty, H. Kirchner, E. Larson, D. Crosslin, M. Andrade, D. Roden, J. Denny, C. Carty, Stephen Hancock, J. Attia, E. Holliday, M. O’Donnell, S. Yusuf, M. Chong, G. Paré, P. Harst, M. Said, R. Eppinga, N. Verweij, H. Snieder, T. Christen, D. Mook-Kanamori, S. Gustafsson, L. Lind, E. Ingelsson, E. Ingelsson, E. Ingelsson, R. Pazoki, O. Franco, A. Hofman, A. Uitterlinden, A. Dehghan, A. Dehghan, A. Teumer, S. Baumeister, M. Dörr, M. Lerch, U. Völker, H. Völzke, J. Ward, J. Pell, Danny Smith, T. Meade, A. Zee, E. Baranova, R. Young, I. Ford, A. Campbell, S. Padmanabhan, M. Bots, D. Grobbee, P. Froguel, P. Froguel, Dorothée Thuillier, B. Balkau, A. Bonnefond, A. Bonnefond, B. Cariou, M. Smart, Y. Bao, M. Kumari, A. Mahajan, P. Ridker, D. Chasman, A. Reiner, L. Lange, M. Ritchie, M. Ritchie, F. Asselbergs, J. Casas, B. Keating, D. Preiss, D. Preiss, A. Hingorani, N. Sattar (2017)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyThe Lancet. Diabetes & Endocrinology, 5
Ž. Reiner, A. Catapano, Guy Backer, I. Graham, M. Taskinen, O. Wiklund, S. Agewall, E. Alegrı́a, M. Chapman, P. Durrington, S. Erdine, J. Halcox, Richard Hobbs, J. Kjekshus, P. Filardi, G. Riccardi, Robert Storey, D. Wood (2013)
ESC/EAS Guidelines for the Management of DyslipidaemiasRevista Portuguesa De Pneumologia, 32
Piepoli (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)Eur Heart J, 37
J. Kostis, J. Dobrzynski (2016)
Prevention of Cataract by Statins.The American journal of cardiology, 117 7
M. Lafeber, R. Webster, F. Visseren, M. Bots, D. Grobbee, W. Spiering, A. Rodgers (2016)
Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular diseaseEuropean Journal of Preventive Cardiology, 23
JS McKinney, WJ. Kostis (2012)
Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trialsJ Am Coll Cardiol, 43
A Corsini, P Ganey, C Ju, N Kaplowitz, D Pessayre, R Roth, PB Watkins, M Albassam, B Liu, S Stancic, L Suter, M. Bortolini (2012)
Current challenges and controversies in drug-induced liver injuryLancet Diabetes Endocrinol, 35
R. Andrade, M. Robles, E. Ulzurrun, M. Lucena (2009)
Drug-induced liver injury: insights from genetic studies.Pharmacogenomics, 10 9
W. Hou, J. Lv, V. Perkovic, Lihong Yang, Na Zhao, M. Jardine, A. Cass, Hong Zhang, Hai-yan Wang (2013)
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.European heart journal, 34 24
D Pastori, L Polimeni, F Baratta, A Pani, M Del Ben, F. Angelico (2015)
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver diseaseJ Hepatol, 47
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto (2003)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 361
B. Gersh (2011)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsYearbook of Medicine, 2011
A. Singh‐Manoux, D. Gimeno, M. Kivimaki, E. Brunner, M. Marmot (2008)
Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II StudyArteriosclerosis, Thrombosis, and Vascular Biology, 28
C. Herrick, M. Litvin, A. Goldberg (2014)
Lipid lowering in liver and chronic kidney disease.Best practice & research. Clinical endocrinology & metabolism, 28 3
M. Serban, Lisandro Colantonio, A. Manthripragada, K. Monda, V. Bittner, M. Banach, Ligong Chen, Lei Huang, R. Dent, Shia Kent, P. Muntner, R. Rosenson (2017)
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.Journal of the American College of Cardiology, 69 11
EJ Brunner, CA Welch, MJ Shipley, S Ahmadi-Abhari, A Singh-Manoux, M. Kivimäki (2017)
Midlife risk factors for impaired physical and cognitive functioning at older ages: a cohort studyBMJ, 72
D. Hackam, M. Woodward, L. Newby, Deepak Bhatt, M. Shao, Eric Smith, A. Donner, M. Mamdani, J. Douketis, H. Arima, J. Chalmers, S. MacMahon, D. Tirschwell, B. Psaty, C. Bushnell, M. Aguilar, D. Capampangan, D. Werring, P. Rango, A. Viswanathan, N. Danchin, Ching-Lan Cheng, Y. Yang, B. Verdel, M. Lai, J. Kennedy, S. Uchiyama, Takenori Yamaguchi, Y. Ikeda, M. Mrkobrada (2011)
Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-AnalysisCirculation, 124
A. Verhulst, P. D'Haese, M. Broe (2004)
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.Journal of the American Society of Nephrology : JASN, 15 9
J. Sidaway, R. Davidson, F. McTaggart, T. Orton, R. Scott, Graham Smith, N. Brunskill (2004)
Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.Journal of the American Society of Nephrology : JASN, 15 9
E Björnsson, EI Jacobsen, E. Kalaitzakis (2012)
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketingCirc Cardiovasc Qual Outcomes, 56
Tushar Acharya, Jian Huang, Steven Tringali, C. Frei, E. Mortensen, I. Mansi (2016)
Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study).The American journal of cardiology, 117 4
P Amarenco, J Bogousslavsky, A Callahan, LB Goldstein, M Hennerici, AE Rudolph, H Sillesen, L Simunovic, M Szarek, KM Welch, JA Zivin (2006)
High-dose atorvastatin after stroke or transient ischemic attackStroke, 355
M. Harris, A. Bron, N. Brown, A. Keech, K. Wallendszus, J. Armitage, S. MacMahon, G. Snibson, R. Collins (1995)
Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.British Journal of Ophthalmology, 79
M. Casula, D. Soranna, G. Corrao, L. Merlino, A. Catapano, E. Tragni (2016)
Statin use and risk of cataract: A nested case-control study within a healthcare database.Atherosclerosis, 251
M. Russo, J. Hoofnagle, Jiezhun Gu, R. Fontana, H. Barnhart, D. Kleiner, N. Chalasani, H. Bonkovsky (2014)
Spectrum of statin hepatotoxicity: Experience of the drug‐induced liver injury networkHepatology, 60
C. Lammert, E. Bjornsson, A. Niklasson, N. Chalasani (2010)
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse eventsHepatology, 51
A Sorokin, JL Brown, PD. Thompson (2007)
Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic reviewPLoS One, 194
D. Pastori, L. Polimeni, F. Baratta, A. Pani, M. Ben, F. Angelico (2015)
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 47 1
(2018)
Premarketing Clinical Evaluation
H. Colhoun, H. Ginsberg, Jennifer Robinson, Lawrence Leiter, D. Müller-Wieland, R. Henry, B. Cariou, M. Baccara-Dinet, R. Pordy, L. Merlet, R. Eckel (2016)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studiesEuropean Heart Journal, 37
T Acharya, J Huang, S Tringali, CR Frei, EM Mortensen, IA. Mansi (2016)
Statin use and the risk of kidney disease with long-term follow-up (8.4-year study)BMJ, 117
Emilia Perdices, I. Medina‐Cáliz, Sofía Hernando, Aida Ortega, Francisca Martín-Ocaña, Jose Navarro, Gloria Peláez, A. Castiella, H. Hallal, Manuel Romero-Gómez, Andrés, González-Jiménez, M. Robles‐Díaz, Isabel Lucena, Raúl Andrade (2014)
Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry.Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, 106 4
P. Elias, M. Elias, R. D'Agostino, L. Sullivan, P. Wolf (2005)
Serum Cholesterol and Cognitive Performance in the Framingham Heart StudyPsychosomatic Medicine, 67
GB Mancini, S Baker, J Bergeron, D Fitchett, J Frohlich, J Genest, M Gupta, RA Hegele, D Ng, GJ Pearson, J Pope, AY. Tashakkor (2016)
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group UpdateHepatology, 32
LB Goldstein, P Amarenco, M Szarek, A Callahan, M Hennerici, H Sillesen, JA Zivin, KM Welch (2008)
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels studyStroke, 70
M. Piepoli, A. Hoes, S. Agewall, C. Albus, C. Brotons, A. Catapano, M. Cooney, U. Corrà, B. Cosyns, Christi Deaton, I. Graham, Michael Hall, F. Hobbs, M. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redón, D. Richter, N. Sattar, Y. Smulders, M. Tiberi, H. Worp, I. Dis, W. Verschuren (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice.Revista espanola de cardiologia, 69 10
R. Mahley (2016)
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism.Arteriosclerosis, Thrombosis, & Vascular Biology
Jennifer Robinson, R. Rosenson, M. Farnier, U. Chaudhari, W. Sasiela, L. Merlet, Kathryn Miller, J. Kastelein (2017)
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.Journal of the American College of Cardiology, 69 5
JD Sturgeon, AR Folsom, WT Longstreth, E Shahar, WD Rosamond, M. Cushman (2007)
Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective StudyCan J Cardiol, 38
(2017)
LifeLines Cohort study
Adriel Guerrero (2016)
2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive SummaryASEAN Heart Journal : Official Journal of the ASEAN Federation of Cardiology, 24
WG Herrington, J Emberson, B Mihaylova, L Blackwell, C Reith, MD Solbu, PB Mark, B Fellström, AG Jardine, C Wanner, H Holdaas, J Fulcher, R Haynes, MJ Landray, A Keech, J Simes, R Collins, C. Baigent (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trialsNeuropsychol, 4
L. Farrer, L. Cupples, J. Haines, B. Hyman, W. Kukull, R. Mayeux, R. Myers, M. Pericak-Vance, N. Risch, C. Duijn (1997)
Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.JAMA, 278 16
A. Matthews, E. Herrett, A. Gasparrini, T. Staa, B. Goldacre, L. Smeeth, K. Bhaskaran (2016)
Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care dataThe BMJ, 353
B. Ference, H. Ginsberg, I. Graham, K. Ray, C. Packard, E. Bruckert, R. Hegele, R. Krauss, F. Raal, H. Schunkert, G. Watts, J. Borén, S. Fazio, J. Horton, L. Masana, S. Nicholls, B. Nordestgaard, B. Nordestgaard, B. Sluis, M. Taskinen, L. Tokgozoglu, U. Landmesser, U. Landmesser, U. Landmesser, U. Laufs, O. Wiklund, O. Wiklund, Jane Stock, M. Chapman, A. Catapano (2017)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 38
A. Sanguankeo, S. Upala, W. Cheungpasitporn, P. Ungprasert, E. Knight (2015)
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-AnalysisPLoS ONE, 10
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
S. Nielsen, B. Nordestgaard (2014)
Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.The lancet. Diabetes & endocrinology, 2 11
S. Palmer, S. Navaneethan, Jonathan Craig, David Johnson, V. Perkovic, J. Hegbrant, G. Strippoli (2014)
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisSão Paulo Medical Journal, 132
JG Robinson, RS Rosenson, M Farnier, U Chaudhari, WJ Sasiela, L Merlet, K Miller, JJ. Kastelein (2017)
Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trialsBMJ Case Rep, 69
M. Tonelli, L. Moye, F. Sacks, T. Cole, G. Curhan (2003)
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.Journal of the American Society of Nephrology : JASN, 14 6
Y Song, H Nie, Y Xu, L Zhang, Y. Wu (2013)
Association of statin use with risk of dementia: a meta-analysis of prospective cohort studiesPsychosom Med, 13
AimsTo objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.Methods and resultsA literature search covering 2000–2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. Randomized controlled trials (RCTs) and genetic studies show that statin therapy is associated with a modest increase in the risk of new-onset diabetes mellitus (about one per thousand patient-years), generally defined by laboratory findings (glycated haemoglobin ≥6.5); this risk is significantly higher in the metabolic syndrome or prediabetes. Statin treatment does not adversely affect cognitive function, even at very low levels of low-density lipoprotein cholesterol and is not associated with clinically significant deterioration of renal function, or development of cataract. Transient increases in liver enzymes occur in 0.5–2% of patients taking statins but are not clinically relevant; idiosyncratic liver injury due to statins is very rare and causality difficult to prove. The evidence base does not support an increased risk of haemorrhagic stroke in individuals without cerebrovascular disease; a small increase in risk was suggested by the Stroke Prevention by Aggressive Reduction of Cholesterol Levels study in subjects with prior stroke but has not been confirmed in the substantive evidence base of RCTs, cohort studies and case–control studies.ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
European Heart Journal – Oxford University Press
Published: Apr 27, 2018
Keywords: Statin; Adverse effects; Glucose homeostasis; Metabolic syndrome; Cognitive function; Renal function; Liver function; Haemorrhagic stroke; Cataract
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.